Debiopharm S.A.

The number of venture capital mega-rounds raised by biopharmaceutical companies has settled into a steady pace of six $100m-plus financings per month, with May matching the number of supersized VC rou

The market for targeted radiotherapy in oncology could soon become a bit more competitive as ITM Isotope Technologies Munich unveiled topline Phase III results for ITM-11 (non-carrier-added 177 Lu-edo

In late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of tre

The radiopharmaceutical space saw a couple of huge deals at the end of last year, and another flurry, albeit on a rather smaller scale, happened this week. On September 12, both Sanofi and ITM Isot